CJC-1295 With DAC vs Without DAC: What the Name Actually Means
In the published literature, CJC-1295 is a long-acting molecule carrying an albumin-binding Drug Affinity Complex (DAC). Products sold as "CJC-1295 no DAC" are a different molecule, Modified GRF (1-29), without that tag. The human and animal studies behind CJC-1295's multi-day duration used the DAC form, so their results cannot be transferred to a no-DAC product. This guide separates the scientific names from the commercial labels and sets out what a certificate of analysis does and does not establish.
Precise Pep Labs Research Editorial Team · November 13, 2026 · 10 min read
Key facts
- In the primary literature, CJC-1295 is the albumin-binding (DAC) molecule; products sold as "CJC-1295 no DAC" are Modified GRF (1-29), a structurally different molecule without the DAC tag.
- The Drug Affinity Complex is a maleimidopropionamide-lysine group that bonds covalently to cysteine-34 of serum albumin, described when CJC-1295 was first characterised in 2005.
- The human studies behind CJC-1295's multi-day half-life (about 6 to 8 days) used the DAC molecule; none investigated the no-DAC form, so those results cannot be attributed to it.
- Analytical-detection studies build methods specifically to resolve sermorelin, CJC-1293, CJC-1295 and tesamorelin, which is external evidence that these names denote different molecules.
- Our blend certificate names and quantifies a "CJC-1295 (No DAC)" component but carries no per-component intact-mass or sequence data, so it does not by itself prove the absence of the DAC group.
The short answer
"CJC-1295" is not one molecule in common use. In the published scientific literature, CJC-1295 is a long-acting molecule that carries an albumin-binding tag called a Drug Affinity Complex (DAC). The products sold online as "CJC-1295 no DAC" are a different molecule — the modified growth-hormone-releasing-factor backbone, Modified GRF (1-29), without that tag.
The distinction matters because the human and animal studies that gave CJC-1295 its reputation for a multi-day duration of action used the DAC-bearing molecule [1][2][3][4]. Those results describe that molecule, and they cannot be transferred to a "no DAC" product, which is structurally different and was not what those studies administered.
This guide separates the scientific nomenclature from the commercial labels, sets out what the DAC modification actually is, and explains why a certificate that names a component "CJC-1295 (No DAC)" is a statement of the supplier's label, not independent proof of its full molecular structure.
This is a research-use-only reference. It describes molecules and the published laboratory record. It contains no dosing, administration, or human-use information, and nothing here is a recommendation to use any compound in people or animals.
One name, several molecules
The confusion starts with a family of closely related analogues of growth-hormone-releasing hormone (GHRH), a hypothalamic hormone of 44 residues whose first 29 amino acids carry the activity.
| Name | What it is | Independently established identity |
|---|---|---|
| Sermorelin | GHRH(1-29), the natural 29-residue active fragment | PubChem CID 16132413, C149H246N44O42S [5] |
| Modified GRF (1-29) | Sermorelin's backbone with four amino-acid substitutions that resist enzymatic breakdown; no albumin tag | Named in detection studies [7][8][9]; commonly sold as "CJC-1295 no DAC" |
| CJC-1295 (with DAC) | Modified GRF (1-29) plus a maleimide-based lysine group that bonds covalently to serum albumin | Defined in Jetté 2005 [1]; PubChem CID 91971820, C165H269N47O46 [6] |
Three points follow from this table, and they are the heart of the article.
- "CJC-1295" in the primary literature means the DAC molecule. When Jetté and colleagues named CJC-1295 in 2005, they named the albumin-binding form [1].
- "CJC-1295 no DAC" is Modified GRF (1-29). Removing the DAC is not a minor variant of CJC-1295; it removes the exact feature that defines CJC-1295 and that produced its long duration of action.
- The commercial label is not a structure. A vial or a certificate that reads "CJC-1295 (No DAC)" is reporting what the material is called, which is a separate question from what a full structural analysis would confirm.
What the Drug Affinity Complex actually is
The chemistry here is specific and was described in the original characterisation study, so it can be stated precisely rather than by metaphor.
Jetté and colleagues synthesised maleimido derivatives of human GRF(1-29) and bonded them to human serum albumin [1]. The molecule they selected and named CJC-1295 is, in their words, "a tetrasubstituted form of hGRF(1-29) with an added N-epsilon-3-maleimidopropionamide derivative of lysine at the C terminus" [1]. In plain terms:
- The backbone is GRF(1-29) with four amino-acid substitutions, which slow its breakdown by the enzyme dipeptidyl-peptidase-IV [1].
- The DAC is the added group: a lysine carrying a maleimidopropionamide. The maleimide reacts with the free thiol on cysteine-34 of circulating albumin, forming a covalent bond to the albumin molecule [1].
Because albumin is a long-lived carrier protein, a peptide tethered to it stays in circulation far longer than the free peptide. In Jetté's rats, CJC-1295 was still detectable in plasma beyond 72 hours, and a Western blot showed the CJC-1295 immunoreactive signal on the albumin band [1]. The DAC is therefore not a loose "anchor"; it is a defined reactive group that forms a specific covalent linkage, and that linkage is the entire mechanism behind the molecule's extended duration.
Modified GRF (1-29) — the "no DAC" material — is the same substituted backbone without this group. It cannot bind albumin covalently, so it does not acquire the long circulating time, and it is a chemically distinct molecule from CJC-1295, not a formulation of it.
CJC-1295 with DAC and without DAC, side by side
The two forms differ on structure, on the research that exists for them, and on how a laboratory confirms which one is in hand.
| Dimension | CJC-1295 (with DAC) | "No DAC" form |
|---|---|---|
| Scientific name | CJC-1295, the albumin-binding analogue [1] | Modified GRF (1-29) [8][9] |
| Common commercial labels | "CJC-1295", "CJC-1295 DAC", "CJC-1295 with DAC" | "CJC-1295 no DAC", "Mod GRF 1-29" |
| Peptide backbone | Tetrasubstituted hGRF(1-29) [1] | Tetrasubstituted hGRF(1-29) |
| Added group | Maleimidopropionamide-lysine — the DAC [1] | None |
| Albumin binding | Covalent, at cysteine-34 of serum albumin [1] | None |
| Reported circulating duration | Multi-day; half-life estimated at about 6 to 8 days in human studies [2][3] | Not established under this name; no comparable published human half-life dataset |
| Published pharmacology | Human and animal studies [2][3][4][10] | None identified for this form specifically |
| How it is confirmed analytically | Intact-mass measurement; the DAC adds a defined mass [8][9] | Intact-mass measurement; the DAC mass is absent |
Every "research evidence" cell for the no-DAC form is empty for a reason: the published record was built on the DAC molecule, and the material sold as "no DAC" has not been studied under that name to the same extent. That asymmetry, not a difference of opinion, is why the two cannot be treated as interchangeable.
Which molecule each study investigated
Grouping the published record by the molecule actually used makes the attribution unambiguous.
Human studies — all of the DAC molecule
- Teichman 2006 pooled two randomised, blinded dose-escalation trials in healthy volunteers between 21 and 61 years of age. The compound tested was the long-acting CJC-1295, whose half-life the authors estimated at roughly 5.8 to 8.1 days; the endpoints were circulating hormone levels, not clinical outcomes [2].
- Ionescu 2006 studied GH pulsatility in healthy men after a single injection of CJC-1295, describing it as the analogue that "binds permanently to endogenous albumin after injection" with a half-life of about 8 days [3].
- Sackmann-Sala 2009 analysed serum proteins in healthy men one week after a CJC-1295 injection, again the long-acting albumin-binding molecule [4].
Every one of these human datasets used the DAC molecule. None investigated Modified GRF (1-29).
Animal research — the DAC molecule
- Alba 2006 treated growth-hormone-releasing-hormone-knockout mice with CJC-1295, described as the analogue that "selectively and covalently binds to endogenous albumin after injection", and reported restoration of growth [10]. This is an animal model, and it used the DAC form.
Analytical and detection studies — distinguishing the named analytes
A separate body of work exists precisely because these analogues are different molecules that laboratories must tell apart.
- Jetté 2005 is the in-vitro and rat identification of CJC-1295 as a distinct, albumin-binding analogue [1].
- Henninge 2010 identified CJC-1295 by mass spectrometry in a seized pharmaceutical preparation, confirming the marketed material against the defined molecule [7].
- Knoop 2016 developed a plasma method that separately targets sermorelin, CJC-1293, CJC-1295 and tesamorelin — four distinct named analytes [8].
- Memdouh 2021 studied the in-vitro metabolism and detection of sermorelin, tesamorelin, CJC-1295 and CJC-1295 with drug affinity complex, treating them as different substances with different metabolites [9].
- Cristea 2023 validated a urine method for tesamorelin, CJC-1295, sermorelin and related species [11].
The detection literature is the clearest external evidence that these names denote different molecules: analytical chemists build methods specifically to resolve them. It does not, by itself, establish which commercial "no DAC" product corresponds to which named analyte — that mapping is an open question addressed below.
Why one molecule's results cannot be moved to the other
Put the two findings together. The pharmacokinetic evidence for a multi-day duration belongs to the DAC molecule [2][3]. The DAC is the covalent albumin tag [1]. A "no DAC" product lacks that tag by definition. Therefore:
- A supplier page, forum post, or study abstract that says only "CJC-1295" is ambiguous until the DAC status is known.
- The long half-life reported for CJC-1295 is a property of the albumin linkage, so it does not describe a no-DAC material.
- Attributing CJC-1295's published pharmacology to a Modified GRF (1-29) product is a category error: it assigns one molecule's experimental results to a structurally different one.
This is the single most important and most commonly mishandled point in material about these compounds, and it is the reason the naming convention matters as much as the chemistry.
A note on nomenclature that remains unsettled
The commercial terminology does not map cleanly onto the scientific names, and honesty requires saying so.
- "Modified GRF (1-29)" and "CJC-1295 no DAC" are generally used for the same non-DAC backbone, but the equivalence is a convention of the market, not a standardised definition.
- The detection literature also names CJC-1293, a separate DAC-type analogue [8], which shows the family is larger than the two-way "DAC vs no DAC" framing suggests.
- Public compound databases carry a record for CJC-1295 (the DAC molecule) [6] and for sermorelin [5], but not a single authoritative record under "Modified GRF (1-29)", so a reader cannot always resolve a commercial label to one database entry.
Where the names are unsettled, the resolution is analytical, not editorial: an intact-mass or sequence measurement on the specific material is what settles which molecule is in a given vial.
What a certificate of analysis does and does not establish
Precise Pep Labs sells a CJC-1295 (no DAC) + Ipamorelin research blend and does not sell a standalone CJC-1295 with DAC product. Its certificate is a useful, honest example of exactly where a certificate's authority ends.
The Kovera Labs report KVR-2026-02AD9E records, for this blend:
- A blend identity line confirmed by LC-MS against the labelled identity "CJC-1295 (No DAC)/Ipamorelin".
- Per-component content by quantitative HPLC: the component labelled CJC-1295 (No DAC) measured 5.04 mg against a 5 mg label, and Ipamorelin 4.99 mg against 5 mg.
- A blend average HPLC purity figure and an endotoxin screen.
Now the limits, stated plainly:
- The certificate identifies the component by its supplied name and confirms that the material is consistent with that identity by the laboratory's method. It does not print a per-component intact mass or amino-acid sequence.
- An intact-mass measurement is the kind of evidence that would distinguish a no-DAC backbone from a DAC-bearing molecule, because the DAC adds a defined mass. The copy on file does not contain that measurement.
- So the certificate does not, on its own, prove the absence of the DAC group. It establishes name, consistency of identity by LC-MS, content and purity — not full molecular structure.
What would confirm the molecular identity is independent per-component intact-mass or sequence data; what the published literature establishes independently is the structure and behaviour of the DAC molecule [1]. Our guides to reading a certificate of analysis and purity versus net content explain what each certificate field does and does not support. We present the certificate as an example of commercial labelling and laboratory documentation, not as structural proof.
Regulatory status, briefly and by form
This section states dated facts from primary sources and links out; it is not legal advice, and none of it implies approval for human use.
- No FDA marketing approval. The FDA has never granted CJC-1295 marketing authorisation, in any form, for any indication.
- 503A compounding review. On December 4, 2024, the FDA's Pharmacy Compounding Advisory Committee reviewed a group of CJC-1295 substances — including the free base and acetate forms and the drug-affinity-complex (DAC) forms — and the FDA's stated position was that none of those substances should be placed on the 503A bulk-substances list used in pharmacy compounding [12][13]. Advisory-committee recommendations are non-binding.
- Bulk-substance safety information. The FDA maintains dated information on bulk drug substances that may present significant safety risks in compounding [14].
- Anti-doping. On the 2026 WADA Prohibited List, growth-hormone-releasing factors — the class that includes CJC-1295 — are banned both in and out of competition [15].
Note that the regulatory sources themselves distinguish the forms where relevant — the FDA review named the DAC and non-DAC substances separately [12]. Evidence or status attached to one named form does not automatically establish the treatment of another.
Limitations
- Abstract-level sourcing. Findings were verified against published abstracts and bibliographic records; full texts were not obtained for this article.
- Nomenclature. The equivalence of "CJC-1295 no DAC" and "Modified GRF (1-29)" is a market convention, and the mapping of commercial labels to specific named analytes is not standardised.
- Certificate scope. Our blend certificate names and quantifies the component; it does not carry per-component intact-mass or sequence data, so it does not independently prove molecular structure.
- No DAC product of our own. We do not sell a standalone CJC-1295 with DAC, so the comparison is conceptual, anchored to the no-DAC component we carry.
Where to find the certificate
The Kovera Labs report for our blend is in our COA Library and linked from the product page. If the lot printed on a vial you hold is not listed, contact us with the lot details and we will locate the corresponding report.
Evidence from our lab reports
Each row is one certificate on file, identified by product and report date. Values are the figures the testing laboratory reported for that lot; they are not re-measured or adjusted here. "Latest COA in Library" and "Earlier COA" describe the certificate's place in the COA Library for that product. The lot currently shipping is identified by each product's inventory batch number, not by which certificate is newest.
| Product | Report date | Test | Purity | Net content | Certificate |
|---|---|---|---|---|---|
| CJC-1295 (no DAC) + Ipamorelin 10mgLatest COA in Library | Aug 5, 2026 | HPLC purity | 99.55% | 10.03 mg | View |
Frequently asked questions
- What does DAC mean in CJC-1295?
- DAC stands for Drug Affinity Complex. It is a chemical group added to the growth-hormone-releasing-factor backbone: a lysine carrying a maleimidopropionamide that reacts with the free thiol on cysteine-34 of serum albumin and forms a covalent bond to it. Because albumin is long-lived, the attached peptide stays in circulation far longer than the free peptide. The DAC was described when CJC-1295 was first characterised in 2005, and it is the feature that defines CJC-1295 in the scientific literature.
- Is "CJC-1295 no DAC" the same as Modified GRF (1-29)?
- They are generally used for the same molecule: the tetrasubstituted GRF(1-29) backbone without the albumin-binding DAC group. However, that equivalence is a convention of the market rather than a standardised scientific definition, and the detection literature also names a separate analogue, CJC-1293. The reliable way to confirm which molecule is in a given vial is an intact-mass or sequence measurement on that material, not the label.
- Do the published CJC-1295 studies apply to the no-DAC version?
- No. The human pharmacokinetic studies that gave CJC-1295 its reputation for a multi-day duration of action used the albumin-binding DAC molecule. The long half-life is a direct consequence of the covalent albumin linkage, which a no-DAC product does not have. Attributing those results to Modified GRF (1-29) assigns one molecule's experimental findings to a structurally different one, which the evidence does not support.
- How are CJC-1295 with and without DAC told apart in a laboratory?
- By mass. The DAC adds a defined chemical group, so the two molecules differ in molecular mass, and an intact-mass measurement by mass spectrometry distinguishes them. Anti-doping laboratories have published methods that separately detect sermorelin, CJC-1293, CJC-1295 and tesamorelin, which shows these analogues are resolvable, distinct analytes rather than one compound under several names.
- What is the regulatory status of CJC-1295?
- The FDA has not granted CJC-1295 marketing authorisation in any form, for any indication. In December 2024 the FDA's Pharmacy Compounding Advisory Committee reviewed a group of CJC-1295 substances, including both the non-DAC and the drug-affinity-complex forms, and the FDA's position was that none of them should be placed on the 503A bulk-substances list used in pharmacy compounding. Growth-hormone-releasing factors, the class that includes CJC-1295, are on the WADA Prohibited List.
- What does our certificate show for the CJC-1295 component?
- The Kovera Labs report for our blend confirms the blend identity by LC-MS against the labelled name, reports the content of the "CJC-1295 (No DAC)" component by quantitative HPLC, gives a blend purity figure and screens endotoxin. It identifies the component by its supplied name; it does not print a per-component intact mass or sequence, so it does not by itself prove the molecule lacks the DAC group. Confirming that would require independent intact-mass or sequence data.
References
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702
- Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone and IGF Research. 2009;19(6):471-477. doi:10.1016/j.ghir.2009.03.001
- PubChem Compound Summary for CID 16132413, Sermorelin (GHRH(1-29); C149H246N44O42S). National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/16132413
- PubChem Compound Summary for CID 91971820, CJC-1295 (C165H269N47O46). National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/91971820
- Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2010;2(11-12):647-650. doi:10.1002/dta.233
- Knoop A, Thomas A, Fichant E, Delahaut P, Schänzer W, Thevis M. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Analytical and Bioanalytical Chemistry. 2016;408(12):3145-3153. doi:10.1007/s00216-016-9377-3
- Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis. 2021;13(11-12):1871-1887. doi:10.1002/dta.3183
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
- Cristea CD, Radu M, Toboc A, Stan C, David V. Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples. Analytical Biochemistry. 2023;682:115336. doi:10.1016/j.ab.2023.115336
- U.S. Food and Drug Administration. December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar. https://www.fda.gov/advisory-committees/advisory-committee-calendar/december-4-2024-meeting-pharmacy-compounding-advisory-committee-12042024
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting briefing materials, December 4, 2024. https://www.fda.gov/media/183583/download
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- World Anti-Doping Agency. The 2026 Prohibited List. International Standard, effective 1 January 2026. https://www.wada-ama.org/en/prohibited-list
How this article was checked
- Written by: Precise Pep Labs Research Editorial Team
- Last reviewed: November 13, 2026
- Published: November 13, 2026
- Last updated: November 13, 2026
- Lab reports cited: 1
- Sources: the numbered references above and the certificates of analysis in the COA Library. Editorial content is reviewed for research-use-only compliance before publication.
Related research materials
Reference materials discussed in this article, each with its certificate of analysis
Related articles
- Research noteComparisons
BPC-157 vs TB-500: Two Different Molecules, and What "TB-500" Really Is
BPC-157 is a defined 15-residue peptide. "TB-500" is a different story: in chemical databases and FDA documents it is a seven-residue acetylated fragment of thymosin β4 (Ac-LKKTETQ), but commercial suppliers often use the name for full-length thymosin β4, a 43-residue protein. This guide sets out the three formal identities, explains the naming ambiguity, and states precisely what our certificates do and do not establish, including an Axiom intact-mass result and its limits.
November 13, 2026 - Research noteComparisons
Selank vs Semax: Molecular Differences and Research Evidence
Selank and Semax share one design feature, a C-terminal Pro-Gly-Pro tail, and little else: Selank is built from the immunoglobulin fragment tuftsin, Semax from a fragment of adrenocorticotropic hormone. Most published work studies one compound or the other, so most of the two literatures cannot be compared at all. Five studies examined both within the same experiment, and those are the only sources supporting direct comparison. This guide sets out what has been compared, what has not, and what the certificates for the two products record.
November 9, 2026 - Research noteHandling and Storage
Peptide Stock Solution Concentration: A Laboratory Reference
A stock solution's concentration is the mass of compound actually present divided by the final volume. For a certificated lot, the best available estimate of that mass is the laboratory's reported net content, not the label. Across 19 single-compound laboratory certificates, reported content ranged from 90.1 % to 116.3 % of the label. This reference covers mass concentration, molarity, dilution and the measurement steps that move a real solution away from its calculated value.
November 13, 2026 - Research noteCompound Guides
Semax Peptide: Structure, ACTH Origin and the Research Record
Semax is a synthetic heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro, derived from adrenocorticotropic hormone with a Pro-Gly-Pro tail added for stability. The literature describes it under two names that look contradictory but refer to the same molecule. Published chemistry shows that acetylating its N-terminus changes copper coordination and removes a protective effect in a cell model, so N-acetyl Semax is a different compound. This guide covers the structure and naming, the preclinical record, the limits of the human reports, and what our certificate does and does not establish.
November 8, 2026
